Cetuximab an EXTREMEly important addition in SCCHN

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1592, 2007-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cetuximab launched for mCRC, approved for SCCHN.

Inpharma, Vol. 1, Iss. 1663, 2008-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Addition of bevacizumab to cetuximab with or without irinotecan improves progression-free and overall survival durations

Inpharma, Vol. 1, Iss. 1609, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Adding docetaxel to induction chemo a winner for SCCHN

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 644, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Cetuximab Extravasation

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 43, Iss. 1, 2013-03 ,pp. : 49-50

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cetuximab: Trichomegaly: case report

Reactions Weekly, Vol. 1, Iss. 1241, 2009-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite